Trial: 202102071

A Phase II/III Study of Peri-operative Nivolumab and Ipilimumab in Patients with Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma

Phase

II/III

Principal Investigator

Park, Haeseong

Disease Site

Esophagus; Other Digestive Organ

Learn more about this study at: clinicaltrials.gov